Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HIV Infections
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 45 years and 125 years
- Gender
- Both males and females
Description
This study will evaluate the effects of cenicriviroc mesylate (CVC) on arterial inflammation in people living with HIV. Participants will be randomized to either the CVC arm (Arm A) or placebo for CVC arm (Arm B). CVC 150 mg or placebo for CVC will be added to the participants' pre-existing antiretr...
This study will evaluate the effects of cenicriviroc mesylate (CVC) on arterial inflammation in people living with HIV. Participants will be randomized to either the CVC arm (Arm A) or placebo for CVC arm (Arm B). CVC 150 mg or placebo for CVC will be added to the participants' pre-existing antiretroviral (ARV) regimens once a day for at least 24 weeks. For participants who are on an efavirenz (EFV)-based regimen, dosing will be 300 mg once a day. Study participants will remain on study treatment for approximately 24 weeks. Study visits may include blood collection, physical examinations, and FDG-PET/CT imaging.
Tracking Information
- NCT #
- NCT04334915
- Collaborators
- Allergan, plc
- Investigators
- Study Chair: Janet Lo, MD, MMSc Massachusetts General Hospital
Get Well Soon